
Globus Medical Presents Data From Long-Term Nuvasive Simplify Disc Study Demonstrating Superiority to Anterior Cervical Discectomy Fusion Procedures
Globus Medical presented positive outcomes from a long-term study on the NuVasive Simplify Cervical Disc at the 38th Annual Meeting of the North American Spine Society (NASS). This comprehensive study reveals favorable clinical results over a five-year period, highlighting a high rate of overall composite success and a significant edge over anterior cervical discectomy fusion (ACDF) procedural outcomes.
The five-year study of Simplify Cervical Disc study’s key findings showed that the Simplify Cervical Disc exhibited statistical superiority over the ACDF control in terms of overall composite success at the five-year mark. Postoperative enhancements in the neck disability index (NDI) and visual analog scale (VAS) were observed at the two-year mark and were consistently maintained for five years. The Simplify Cervical Disc group displayed significantly lower NDI and VAS scores at the five-year point compared to the ACDF control. The Simplify Disc group saw increased disc height and flexion/extension range of motion after surgery, maintaining levels above those recorded preoperatively throughout the follow-up period. Additionally, no device failures were noted in the Simplify Disc group.
Dr. Pierce Nunley of the Spine Institute of Louisiana expressed his enthusiasm for the durability of the positive outcomes observed at 24 months and looked forward to further success beyond the 60-month mark. He emphasized that the study reinforces the outstanding and long-lasting clinical benefits of Simplify Cervical Disc over ACDF. It’s worth noting that Simplify Cervical Disc has demonstrated the highest overall clinical success rate for both one and two-level procedures compared to any other approved cervical disc. Major competitors in the space include Medtronic and Zimmer Biomet.
Simplify Disc initially received approval for one-level use in September 2020, achieving an overall success rate of 93.0% versus 73.6% for fusion. Subsequently, in April 2021, it received two-level approval, once again demonstrating its superiority over ACDF with a success rate of 86.7% versus 77.1%.